TIL therapy

BIOLOGICAL2 trials

Sponsors

Shanghai Juncell Therapeutics, Inge Marie Svane

Conditions

Advanced Solid TumorAdverse Drug EventEfficacyImmunotherapyMelanoma MetastaticSafetyTumor Infiltrating Lymphocytes

Phase 1

A Phase I Study of GC101 TIL in Advanced Solid Tumors

CompletedNCT05417750

Shanghai Juncell TherapeuticsAdvanced Solid Tumor, Adverse Drug Event, Efficacy +3

Start: 2022-10-12End: 2025-10-30Updated: 2025-12-10

T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma

RecruitingNCT06783270

Inge Marie SvaneMelanoma Metastatic

Start: 2024-12-16End: 2028-01-01Target: 10Updated: 2025-01-20

Related Papers

IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer.

2024-05-206 citations

63TiP A phase I study of tumor-infiltrating lymphocytes (TILs) in advanced solid tumors used an optimized regimen: MIZAR trial

Immuno-Oncology Technology2023-12-01